Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Remix Therapeutics
Biotech
Former Roche oncology head turns to Tubulis—Chutes & Ladders
Former Roche oncology head turns to Tubulis. Argenx CEO passes baton to operating chief. Longtime Charles River leader eyes retirement.
Darren Incorvaia
,
Zoey Becker
Jan 9, 2026 8:30am
Ex-Eisai leader to be new NextPoint CEO—Chutes & Ladders
Feb 2, 2024 9:30am
Get ready for the Roche (Remix), a $30M small molecule deal
Jan 3, 2024 7:00am
New year, new C-suite execs—Chutes & Ladders
Jan 6, 2023 9:30am
Alchemab CEO resigns citing 'personal reasons'—Chutes & Ladders
May 27, 2022 9:30am
Remix closes $70 million series B but what's in the pipeline?
May 17, 2022 6:45am